The sale by KalVista Pharmaceuticals’ Chief Development Officer reflects option exercises, not a net increase in holdings.
KalVista Pharmaceuticals (NASDAQ:KALV) Chief Development Officer Christopher Yea sold 33,800 shares for approximately $905,000 on May 27, 2026, following the exercise of vested options. The transaction was executed at a weighted average price of $26.78 per share, according to regulatory filings.
This marks Yea’s second open-market sale, with a prior transaction involving 39,886 shares. Most of his historical trades were administrative, not outright sales. The recent sale reduces his direct holdings by 28.84% over the past year, though the pace of sales remains limited.
After the sale, Yea retains 229,918 shares, valued at roughly $6.16 million as of the transaction date. No exercisable options or indirect holdings remain.